6472 Stock Overview
Researches and develops, manufactures, distributes, and sells pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Bora Pharmaceuticals Co., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$737.00 |
| 52 Week High | NT$975.00 |
| 52 Week Low | NT$612.00 |
| Beta | 0.75 |
| 1 Month Change | -5.51% |
| 3 Month Change | -3.41% |
| 1 Year Change | 14.80% |
| 3 Year Change | 467.89% |
| 5 Year Change | 1,045.66% |
| Change since IPO | 1,538.80% |
Recent News & Updates
Recent updates
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem
Nov 21
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?
Oct 04Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects
Jul 18Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?
Jun 13Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Apr 10Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Apr 08Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Mar 14Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?
Apr 30Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?
Mar 17Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment
Feb 17
New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)
Jan 27Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt
Jan 19We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings
Dec 29Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?
Dec 09Shareholder Returns
| 6472 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.9% | -0.01% | -2.1% |
| 1Y | 14.8% | -2.7% | 25.6% |
Return vs Industry: 6472 exceeded the TW Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: 6472 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 6472 volatility | |
|---|---|
| 6472 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6472 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6472's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Bobby Sheng | www.bora-corp.com |
Bora Pharmaceuticals Co., LTD. researches and develops, manufactures, distributes, and sells pharmaceuticals worldwide. The company operates through Sales, Contract Development & Manufacturing Organization, and Other segments.
Bora Pharmaceuticals Co., LTD. Fundamentals Summary
| 6472 fundamental statistics | |
|---|---|
| Market cap | NT$76.16b |
| Earnings (TTM) | NT$3.90b |
| Revenue (TTM) | NT$16.71b |
19.5x
P/E Ratio4.6x
P/S RatioIs 6472 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6472 income statement (TTM) | |
|---|---|
| Revenue | NT$16.71b |
| Cost of Revenue | NT$9.18b |
| Gross Profit | NT$7.53b |
| Other Expenses | NT$3.63b |
| Earnings | NT$3.90b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 37.74 |
| Gross Margin | 45.08% |
| Net Profit Margin | 23.35% |
| Debt/Equity Ratio | 128.3% |
How did 6472 perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 04:36 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bora Pharmaceuticals Co., LTD. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Capital Securities Corporation |
| Jianzheng Wu | Capital Securities Corporation |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |